Market closedNon-fractional
Theravance Biopharma/TBPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Theravance Biopharma
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Ticker
TBPH
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
South San Francisco, United States
Employees
99
Website
www.theravance.com
TBPH Metrics
BasicAdvanced
$497M
Market cap
-
P/E ratio
-$0.87
EPS
0.36
Beta
-
Dividend rate
Price and volume
Market cap
$497M
Beta
0.36
Financial strength
Current ratio
5.738
Quick ratio
5.292
Long term debt to equity
21.399
Total debt to equity
21.399
Interest coverage (TTM)
-16.95%
Management effectiveness
Return on assets (TTM)
-5.65%
Return on equity (TTM)
-15.56%
Valuation
Price to revenue (TTM)
8.572
Price to book
2.4
Price to tangible book (TTM)
2.4
Price to free cash flow (TTM)
-28.594
Growth
Revenue change (TTM)
26.65%
Earnings per share change (TTM)
-106.98%
3-year revenue growth (CAGR)
-2.45%
3-year earnings per share growth (CAGR)
-41.44%
What the Analysts think about TBPH
Analyst Ratings
Majority rating from 5 analysts.
TBPH Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$15M
-17.14%
Net income
-$12M
36.47%
Profit margin
-80.00%
64.71%
TBPH Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.28
-$0.17
-$0.17
-$0.24
-
Expected
-$0.21
-$0.21
-$0.15
-$0.25
-$0.21
Surprise
33.33%
-18.92%
14.35%
-5.51%
-
TBPH News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Theravance Biopharma stock?
Theravance Biopharma (TBPH) has a market cap of $497M as of July 27, 2024.
What is the P/E ratio for Theravance Biopharma stock?
The price to earnings (P/E) ratio for Theravance Biopharma (TBPH) stock is 0 as of July 27, 2024.
Does Theravance Biopharma stock pay dividends?
No, Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Theravance Biopharma dividend payment date?
Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Theravance Biopharma?
Theravance Biopharma (TBPH) has a beta rating of 0.36. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Theravance Biopharma stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.